About: Impact of viral coinfection and macrolide-resistant mycoplasma infection in children with refractory Mycoplasma pneumoniae pneumonia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Impact of viral coinfection and macrolide-resistant mycoplasma infection in children with refractory Mycoplasma pneumoniae pneumonia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Impact of viral coinfection and macrolide-resistant mycoplasma infection in children with refractory Mycoplasma pneumoniae pneumonia
Creator	Wang, Jing Shen, Nan Cao, Qing Li, Biru Luo, Lijuan Tao, Yue Chen, Wenjuan Zhao, Ruike Zhou, Yajuan
source	Medline; PMC
abstract	BACKGROUND: Cases of refractory Mycoplasma pneumoniae pneumonia have been increasing recently; however, whether viral coinfection or macrolide-resistant M. infection contribute to the development of refractory M. pneumoniae pneumonia remains unclear. This study aimed to investigate the impacts of viral coinfection and macrolide-resistant M. pneumoniae infection on M. pneumoniae pneumonia in hospitalized children and build a model to predict a severe disease course. METHODS: Nasopharyngeal swabs or sputum specimens were collected from patients with community-acquired pneumonia meeting our protocol who were admitted to Shanghai Children’s Medical Center from December 1, 2016, to May 31, 2019. The specimens were tested with the FilmArray Respiratory Panel, a multiplex polymerase chain reaction assay that detects 16 viruses, Bordetella pertussis, M. pneumoniae, and Chlamydophila pneumoniae. Univariate and multivariate logistic regression models were used to identify the risk factors for adenovirus coinfection and macrolide-resistant mycoplasma infection. RESULTS: Among the 107 M. pneumoniae pneumonia patients, the coinfection rate was 56.07%, and 60 (60/107, 56.07%) patients were infected by drug-resistant M. pneumoniae. Adenovirus was the most prevalent coinfecting organism, accounting for 22.43% (24/107). The classification tree confirmed that viral coinfection was more common in patients younger than 3 years old. Adenovirus coinfection and drug-resistant M. pneumoniae infection occurred more commonly in patients with refractory M. pneumoniae pneumonia (P = 0.019; P = 0.001). A prediction model including wheezing, lung consolidation and extrapulmonary complications was used to predict adenovirus coinfection. The area under the receiver operating characteristic curve of the prediction model was 0.795 (95% CI 0.679–0.893, P < 0.001). A prolonged fever duration after the application of macrolides for 48 h was found more commonly in patients infected by drug-resistant M. pneumoniae (P = 0.002). A fever duration longer than 7 days was an independent risk factor for drug-resistant Mycoplasma infection (OR = 3.500, 95% CI = 1.310–9.353, P = 0.012). CONCLUSIONS: The occurrence of refractory M. pneumoniae pneumonia is associated with adenovirus coinfection and infection by drug-resistant M. pneumoniae. A prediction model combining wheezing, extrapulmonary complications and lung consolidation can be used to predict adenovirus coinfection in children with M. pneumoniae pneumonia. A prolonged fever duration indicates drug-resistant M. pneumoniae infection, and a reasonable change in antibiotics is necessary.
has issue date	2020-08-26(xsd:dateTime)
bibo:doi	10.1186/s12879-020-05356-1
bibo:pmid	32847534
has license	cc-by
sha1sum (hex)	d62d939f6bfe5275a3f7e1e2f68a9bd66fd5f5c1
schema:url	https://doi.org/10.1186/s12879-020-05356-1
resource representing a document's title	Impact of viral coinfection and macrolide-resistant mycoplasma infection in children with refractory Mycoplasma pneumoniae pneumonia
has PubMed Central identifier	PMC7447613
has PubMed identifier	32847534
schema:publication	BMC Infect Dis
resource representing a document's body	covid:d62d939f6bfe5275a3f7e1e2f68a9bd66fd5f5c1#body_text
is schema:about of	named entity 'Univariate' named entity 'protocol' named entity 'Shanghai' named entity 'mycoplasma infection' named entity 'coinfection' named entity 'CASES' named entity 'INCREASING' named entity 'DEVELOPMENT' named entity 'ADENOVIRUS' named entity 'PREDICT' named entity 'POLYMERASE CHAIN REACTION ASSAY' named entity 'IMPACTS' named entity 'PNEUMONIA' named entity 'CHILDREN' named entity 'PNEUMONIAE' named entity 'CONTRIBUTE ' named entity '2019' named entity 'METHODS' named entity 'TO INVESTIGATE' named entity 'SPUTUM' named entity '27S' named entity 'MODEL' named entity 'MEETING' covid:arg/d62d939f6bfe5275a3f7e1e2f68a9bd66fd5f5c1 named entity 'sputum' named entity 'tested' named entity 'M. pneumoniae' named entity 'Bordetella' named entity 'coinfection' named entity 'mycoplasma infection' named entity 'disease' named entity 'macrolide' named entity 'pneumonia' named entity 'macrolide' named entity 'logistic regression' named entity 'refractory' named entity 'sputum' named entity 'infection' named entity 'polymerase chain reaction' named entity 'M. pneumoniae' named entity 'mycoplasma' named entity 'macrolide' named entity 'coinfection' named entity 'Mycoplasma pneumoniae' named entity 'community-acquired pneumonia' named entity 'immune response' named entity 'community-acquired pneumonia' named entity 'clinical symptoms' named entity 'coinfections' named entity 'macrolide antibiotics' named entity 'RSV' named entity 'mutation' named entity 'adverse reactions' named entity 'infection' named entity 'nucleotide' named entity 'severe pneumonia' named entity 'standard deviations' named entity 'OC43' named entity 'refractory' named entity 'RT-PCR' named entity 'severe pneumonia' named entity 'fever' named entity '95% CI' named entity 'mutation rate' named entity 'alternative medicines' named entity 'enterovirus' named entity 'coinfected' named entity 't-tests' named entity 'leukocyte' named entity 'penicillin' named entity 'ROC' named entity 'risk factors' named entity 'fluoroquinolones'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software